FDA approves first adenoviral vector-based gene therapy for high-risk Bacillus Calmette-Guérin unresponsive non-muscle invasive bladder cancer

Drug

Adstiladrin (nadofaragene firadenovec-vncg) · Adenovirus vector

Condition

Genitourinary